5Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemia Net. Blood, 2006 , 108 (6) : 1809-1820.
6Thomas J, Wang L, Clark RE, et al. Active transport of imatinib into and out of cells:Implications for drug resistance. Blood,2004, 104(12) :3739-3745.
7Crossman LC, Druker BJ, Deininger MW, et al. hOCT 1 and resistance to imatinib. Blood,2005 ; 106(3):1133-1134.
8Wang L, Giannoudis A, Lane S, et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to Imatinib in chronic myeloid leukemia. Clin Pharmacol Ther,2008;83(2) :258-264.
9White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to Imatinib have low OCT-1 activity: higher doses of Imatinih may overcome the negative Impact of low OCT-1 activity. Blood, 2007 , 110(2) : 4064-4072.
10Melo JV, Chuah C. Resistance to imatinib mesylate in chronic myeloid leukaemia[ J]. Cancer lett, 2007, 249(2) : 121 - 127.
